Evidence map›Paper›PMID 35954475›Full record

ReviewCancers2022

Pathogenic Roles of RNA-Binding Proteins in Sarcomas.

Yu Hai, Asuka Kawachi, Xiaodong He, Akihide Yoshimi

Open access · goldAbstract readReview
In one paragraph

Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Role of the RNA-binding protein family in gynecologic cancers.American journal of cancer research · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Yu HaiCancer RNA Research Unit, National Cancer Center Research Institute, Tokyo 104-0045, Japan.
Asuka KawachiCancer RNA Research Unit, National Cancer Center Research Institute, Tokyo 104-0045, Japan.
Xiaodong HeDepartment of Physical and Chemical Inspection, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, China.
Akihide YoshimiCancer RNA Research Unit, National Cancer Center Research Institute, Tokyo 104-0045, Japan.ORCID 0000-0002-0664-7281
National Cancer Centre Japan · JPShandong University · CN

Funding

Japan Agency for Medical Research and Development JP22am0401007Japan Agency for Medical Research and Development JP22jm0210085Japan Science and Technology Agency 22-221036124Japan Society for the Promotion of Science 19K24691Japan Society for the Promotion of Science 21H04828National Cancer Center 2020-A-2
6 · The paper itself

Abstract

RNA-binding proteins (RBPs) are proteins that physically and functionally bind to RNA to regulate the RNA metabolism such as alternative splicing, polyadenylation, transport, maintenance of stability, localization, and translation. There is accumulating evidence that dysregulated RBPs play an essential role in the pathogenesis of malignant tumors including a variety of types of sarcomas. On the other hand, prognosis of patients with sarcoma, especially with sarcoma in advanced stages, is very poor, and almost no effective standard treatment has been established for most of types of sarcomas so far, highlighting the urgent need for identifying novel therapeutic targets based on the deep understanding of pathogenesis. Therefore, defining the network of interactions between RBPs and disease-related RNA targets will contribute to a better understanding of sarcomagenesis and identification of a novel therapeutic target for sarcomas.

Indexed as

Ewing sarcomanon-coding RNApolyadenylationrhabdomyosarcomaRNA-binding proteinsarcomasplicingsynovial sarcomastranslation

Identifiers

PMID35954475
PMCPMC9367343
OpenAlexW4290466565

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.